England is on track to eliminate hepatitis C as a public health threat by 2030 by targeting drug treatment centers for testing and treatment. In contrast, the US lacks a national elimination plan, with only 5% of substance use facilities offering hepatitis C testing in 2024.
Key barriers include workforce shortages, complex billing, and lack of consistent funding. Experts urge the US to adopt England's model of integrated care at opioid treatment programs.